Septerna is a pre-revenue biotech with elite cash conversion (FCF margin 33%) and strong analyst support, but a consistent earnings miss streak and high short interest of 11% create meaningful downside risk that outweighs the 10.5% upside at current prices.
Thesis pillars
- Analyst Conviction Price Target Upside↓Deteriorating
- Fcf Positive Pre Revenue Biotech→Stable
- High Implied Volatility Options Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 9, 2026
Septerna, Inc. (SEPN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $44.25, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.6%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule... Read more
Sell if holding. At $44.25, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.6%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 5/8 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Septerna, Inc.
Latest news
- NEWS JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48 — benzinga Aug 19, 2026 positive
- NEWS Jones Trading Maintains Buy on Septerna, Raises Price Target to $62 — benzinga Aug 13, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $50 — benzinga Aug 12, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $60 — benzinga Aug 12, 2026 positive
- NEWS Guggenheim Maintains Buy on Septerna, Raises Price Target to $51 — benzinga Aug 11, 2026 positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $44.25, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.6%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $41.15. Score 4.8/10, moderate confidence.
Analyst target: $47.17 (+6.6% upside). Prior stop was $41.15. Stop-loss: $41.15.
Thin upside margin: 6.6%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Consecutive earnings misses (2).
Septerna, Inc. trades at a P/E of N/A (forward -22.8). TrendMatrix value score: 3.6/10. Verdict: Sell.
16 analysts cover SEPN with a consensus score of 4.3/5. Average price target: $54.
What does Septerna, Inc. do?Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral...
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.